The proposed synergies include, for example, the addition of IL-2 to immune checkpoint inhibitors, such as pembrolizumab, or to adoptive cellular therapy, in particular, Tumor-Infiltrating Lymphocyte (TIL) therapy [7,73]. This evidence concerns the gene IL2 and neoplasm.